MDXHHealthcare · Diagnostics & ResearchThe 6 Wall Street analysts covering MDxHealth SA hold a median 12-month price target of $1 — +539.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 4 Nov 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores MDxHealth SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (89): Smaller than most of the companies we track.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MDXH, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +539.4% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Oct 2026 | BTIG | Downgrade | Neutral | — |
| 19 Oct 2026 | BTIG | Downgrade | Neutral | — |
| 21 Aug 2026 | BTIG | Maintains | Buy | $4.00 → $2.00 |
| 21 Aug 2026 | BTIG | Maintains | Buy | — |
| 14 Aug 2026 | Lake Street | Maintains | Buy | — |
| 14 Aug 2026 | Lake Street | Maintains | Buy | $5.00 → $3.00 |
| 14 May 2026 | BTIG | Maintains | Buy | — |
| 14 May 2026 | Lake Street | Maintains | Buy | — |
| 14 May 2026 | TD Cowen | Maintains | Buy | — |
| 23 Dec 2025 | BTIG | Reiterates | Buy | — |
| 13 Nov 2025 | BTIG | Maintains | Buy | — |
| 13 Nov 2025 | Lake Street | Maintains | Buy | — |
| 13 Nov 2025 | TD Cowen | Maintains | Buy | — |
| 7 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 31 Oct 2024 | Lake Street | Initiates | Buy | — |
| 7 Mar 2024 | BTIG | Maintains | Buy | — |
| 7 Mar 2024 | Piper Sandler | Maintains | Overweight | — |
| 9 Nov 2023 | Piper Sandler | Maintains | Overweight | $10 → $6.00 |
| 20 June 2023 | BTIG | Maintains | Buy | — |
| 31 May 2023 | TD Cowen | Initiates | Outperform | $7.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MDXH appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 94% of US stocks
Cheaper than 94% of US stocks
Cheaper than 83% of US stocks
Higher than 33% of US stocks
Higher than 39% of US stocks
Higher than 79% of US stocks
Higher than 22% of US stocks
Higher than 13% of US stocks
Higher than 99% of US stocks
Higher than 27% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MDxHealth SA has a market value of $15.1M and an enterprise value of $94.8M.
Revenue in the twelve months to 30 June 2026: $111.6M. The latest quarter grew 2.3% year on year.
Net income over the same four quarters: −$37.3M, a −33.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.72.
Free cash flow in the twelve months to 30 June 2026: −$6.0M.
MDxHealth SA spent $0.0 on dividends in the twelve months to 30 June 2026.
Trailing P/E: −0.2×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%.
MDxHealth SA employs 364 people — $307K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MDxHealth SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MDxHealth announced it will release financial results for the third quarter ended September 30, 2026, after market close on November 12. The company will host a conference call and webcast with live Q&A at 4:30 p.m. ET / 22:30 CET that day.
Why it matters — MDXH watchers can note the timing and access details for the quarterly results and corporate update call.
MDxHealth expects preliminary, unaudited third-quarter 2026 revenue from continuing operations of approximately $22.7 million, matching the $22.7 million reported for the year-earlier quarter. The company suspended its full-year 2026 revenue guidance of $110–115 million.
Why it matters — The update reports flat year-over-year quarterly revenue while removing the company’s full-year revenue outlook.
The 6 Wall Street analysts covering MDxHealth SA have a median 12-month price target of $1, with estimates ranging from $0.5 to $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering MDxHealth SA, 1 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MDxHealth SA 51 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, MDxHealth SA ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +539.4% from the last close, and Ticker Nerd's factor model ranks MDxHealth SA 51 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MDxHealth SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDXH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.5 to $1 over the next 12 months.
MDxHealth SA is a commercial-stage precision diagnostics company focused on molecular testing for urologic diseases. MDxHealth SA develops and commercializes diagnostic solutions that help physicians assess the presence, risk, and management of prostate cancer, bladder cancer, and urinary tract infections.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Mdxhealth to Release Third Quarter 2026 Financial Results on November 12". MDxHealth announced it will release financial results for the third quarter ended September 30, 2026, after market close on November 12. The company will host a conference call and webcast with live Q&A at 4:30 p.m. ET / 22:30 CET that day.
MDxHealth SA is a commercial-stage precision diagnostics company focused on molecular testing for urologic diseases. MDxHealth SA develops and commercializes diagnostic solutions that help physicians assess the presence, risk, and management of prostate cancer, bladder cancer, and urinary tract infections. Its portfolio includes tissue- and urine-based tests that use genomic, epigenetic, exosomal, and other molecular technologies to support more informed clinical decision-making. The company serves healthcare providers and patients across the United States, Europe, and other international markets, with laboratory and commercial operations supporting the delivery of its tests. MDxHealth SA plays a role in the broader diagnostics market by providing actionable molecular information designed to improve the precision of cancer and infection diagnosis and treatment planning.
CEO Mr. Michael K. McGarrity · 364 employees · Belgium · https://mdxhealth.com